The association between HCT outcomes and JAK2V617F mutation allele burden in patients with MF by disease subtype before and after the introduction of JAK inhibitors (proxy year at HCT before 2013 and 2013+)
| . | OS∗ . | NRM† . | Relapse‡ . | |||
|---|---|---|---|---|---|---|
| HR1 . | P . | HR2 (95% CI) . | P . | HR3 (95% CI) . | P . | |
| PMF before 2013 | ||||||
| Positive vs negative | 1.22 (0.87-1.72) | .24 | 1.20 (0.79-1.82) | .38 | 1.01 (0.65-1.57) | .95 |
| <60% vs negative | 1.23 (0.82-1.81) | .32 | 1.47 (0.92-2.34) | .12 | 0.86 (0.49-1.52) | .61 |
| ≥60% vs negative | 1.22 (0.83-1.79) | .30 | 0.97 (0.59-1.60) | .97 | 1.15 (0.69-1.90) | .69 |
| PMF 2013+ | ||||||
| Positive vs negative | 0.82 (0.58-1.15) | .25 | 0.91 (0.59-1.40) | .68 | 1.02 (0.69-1.49) | .92 |
| <60% vs negative | 0.77 (0.51-1.15) | .20 | 0.74 (0.43-1.26) | .26 | 0.92 (0.59-1.43) | .73 |
| ≥60% vs negative | 0.88 (0.58-1.34) | .56 | 1.12 (0.68-1.85) | .64 | 1.16 (0.73-1.86) | .52 |
| PPV-MF before 2013§ | ||||||
| ≥90% vs <90% | 0.94 (0.39-2.24) | .89 | 1.15 (0.39-3.41) | .80 | 1.11 (0.38-3.23) | .85 |
| PPV-MF 2013+§ | ||||||
| ≥90% vs <90% | 0.98 (0.44-2.18) | .96 | 0.34 (0.12-0.99) | .05 | 1.82 (0.81-4.09) | .14 |
| PET-MF before 2013 | ||||||
| Positive vs negative | 1.12 (0.50-2.49) | .78 | 0.87 (0.25-3.04) | .83 | 2.19 (0.67-7.11) | .19 |
| <60% vs negative | 1.47 (0.52-4.15) | .46 | 0.93 (0.19-4.47) | .92 | 1.98 (0.49-8.06) | .34 |
| ≥60% vs negative | 0.94 (0.37-2.39) | .90 | 0.83 (0.21-3.35) | .80 | 2.37 (0.64-8.83) | .20 |
| PET-MF 2013+ | ||||||
| Positive vs negative | 1.78 (0.86-3.68) | .12 | 3.53 (1.29-10.48) | .02 | 1.62 (0.79-3.31) | .18 |
| <60% vs negative | 1.62 (0.70-3.77) | .26 | 1.99 (0.54-7.31) | .30 | 1.58 (0.69-3.61) | .27 |
| ≥60% vs negative | 2.04 (0.79-5.25) | .14 | 7.65 (2.10-27.82) | .002 | 1.69 (0.59-4.87) | .33 |
| . | OS∗ . | NRM† . | Relapse‡ . | |||
|---|---|---|---|---|---|---|
| HR1 . | P . | HR2 (95% CI) . | P . | HR3 (95% CI) . | P . | |
| PMF before 2013 | ||||||
| Positive vs negative | 1.22 (0.87-1.72) | .24 | 1.20 (0.79-1.82) | .38 | 1.01 (0.65-1.57) | .95 |
| <60% vs negative | 1.23 (0.82-1.81) | .32 | 1.47 (0.92-2.34) | .12 | 0.86 (0.49-1.52) | .61 |
| ≥60% vs negative | 1.22 (0.83-1.79) | .30 | 0.97 (0.59-1.60) | .97 | 1.15 (0.69-1.90) | .69 |
| PMF 2013+ | ||||||
| Positive vs negative | 0.82 (0.58-1.15) | .25 | 0.91 (0.59-1.40) | .68 | 1.02 (0.69-1.49) | .92 |
| <60% vs negative | 0.77 (0.51-1.15) | .20 | 0.74 (0.43-1.26) | .26 | 0.92 (0.59-1.43) | .73 |
| ≥60% vs negative | 0.88 (0.58-1.34) | .56 | 1.12 (0.68-1.85) | .64 | 1.16 (0.73-1.86) | .52 |
| PPV-MF before 2013§ | ||||||
| ≥90% vs <90% | 0.94 (0.39-2.24) | .89 | 1.15 (0.39-3.41) | .80 | 1.11 (0.38-3.23) | .85 |
| PPV-MF 2013+§ | ||||||
| ≥90% vs <90% | 0.98 (0.44-2.18) | .96 | 0.34 (0.12-0.99) | .05 | 1.82 (0.81-4.09) | .14 |
| PET-MF before 2013 | ||||||
| Positive vs negative | 1.12 (0.50-2.49) | .78 | 0.87 (0.25-3.04) | .83 | 2.19 (0.67-7.11) | .19 |
| <60% vs negative | 1.47 (0.52-4.15) | .46 | 0.93 (0.19-4.47) | .92 | 1.98 (0.49-8.06) | .34 |
| ≥60% vs negative | 0.94 (0.37-2.39) | .90 | 0.83 (0.21-3.35) | .80 | 2.37 (0.64-8.83) | .20 |
| PET-MF 2013+ | ||||||
| Positive vs negative | 1.78 (0.86-3.68) | .12 | 3.53 (1.29-10.48) | .02 | 1.62 (0.79-3.31) | .18 |
| <60% vs negative | 1.62 (0.70-3.77) | .26 | 1.99 (0.54-7.31) | .30 | 1.58 (0.69-3.61) | .27 |
| ≥60% vs negative | 2.04 (0.79-5.25) | .14 | 7.65 (2.10-27.82) | .002 | 1.69 (0.59-4.87) | .33 |
CMV, cytomegalovirus; GVHD, graft-versus-host disease.
Model: adjusted for patient age, year of HCT, splenectomy before HCT, DIPSS, recipient-donor CMV serostatus match, donor type.
Model adjusted for age, CMV serostatus match, year of HCT, graft type, splenectomy, donor type, and conditioning intensity.
Model adjusted for splenectomy, conditioning intensity, DIPSS, GVHD prophylaxis, and stratified on year of HCT.
Mutation negative patients were excluded because of small number (N = 4; all died in the first 12 months).